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ABSTRACT COVID-PCD is a participatory study initiated by people with primary ciliary dyskinesia
(PCD) who have an essential vote in all stages of the research from the design of the study to the
recruitment of participants, and interpretation and communication of the study results. COVID-PCD aims
to collect epidemiological data in real-time from people with PCD throughout the pandemic to describe
incidence of coronavirus disease 2019 (COVID-19), symptoms and course of disease; identify risk factors
for prognosis; and assess experiences, wishes and needs.
The study is advertised through patient support groups and participants register online on the study
website (www.covid19pcd.ispm.ch). The study invites persons of any age from anywhere in the world with
a suspected or confirmed PCD. A baseline questionnaire assesses details on PCD diagnosis, habitual
symptoms and COVID-19 episodes that occurred before study entry. Afterwards, participants receive a
weekly follow-up questionnaire with questions on incident severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infections, current symptoms, social contact behaviour and physical activity. Occasional
thematic questionnaires are sent out focussing on emerging questions of interest chosen by people with
PCD. In case of hospitalisation, patients or family members are asked to obtain a hospital report. Results
are continuously analysed and summaries put online.
The study started recruitment on April 30, 2020, and 556 people with PCD completed the baseline
questionnaire by November 2, 2020. The COVID-PCD study is a participatory study that follows people
with PCD during the COVID-19 pandemic, helps to empower affected persons, and serves as a platform
for communication between patients, physicians and researchers.
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The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has by November 2020 spread globally with >47 million infected people in
over 200 countries and territories. The severity of COVID-19 ranges from asymptomatic to severe disease
[1, 2], and elderly people and individuals with pre-existing chronic health conditions are at increased risk
of a severe disease course [3–7]. COVID-19 has also been associated with impaired lung function after
recovery, even in people without pre-existing health conditions [8, 9].
Primary ciliary dyskinesia (PCD) is a rare genetic multi-system disease that affects about 1 in 10,000
people. It leads to chronic upper and lower airway disease, laterality defects including congenital heart
disease and other health problems [10–13]. While some patients are relatively mildly affected, others
develop severe irreversible lung disease from an early age with repeated infections resulting in reduced
lung function, bronchiectasis and sometimes oxygen dependency with some requiring lung transplantation
[14–19]. We do not know how SARS-CoV-2 affects people with PCD and whether severity of PCD, age
and other patient characteristics influence COVID-19 disease course. PCD registries and research
databases are not designed for a longitudinal collection of patient-reported information on symptoms and
health behaviour in real-time [20]. However, such data are needed to comprehensively understand the
impact of SARS-CoV-2 on people with PCD. Patient-reported data are also essential to understand how
public health measures that aim to reduce the spread of COVID-19 are adopted by people with PCD, and
how the pandemic affects their life and medical care. During the early phase of the pandemic (March and
April, 2020), people with PCD all over the world were worried and desperate to understand the effects of
SARS-CoV-2 on persons with this rare disease. Given the lack of evidence, patient support groups
approached researchers and proposed to set up a study together.
Research projects that focus on rare diseases can be challenging due to the limited number of people with
the disease and their geographical dispersion [21]. It is therefore important to make the study as relevant
as possible to the participants and ensure that participation is feasible. This can be helped by using a
participatory approach in which study participants are engaged in all stages of a research project from the
design of the study to shaping the content and interpreting results. Participatory research methods have
been associated with better networking between participants, higher relevance for affected people, patient
empowerment and higher participation rates [22–24]. COVID-PCD has been designed as a collaboration
of epidemiologists, healthcare specialists and people with PCD. It is a longitudinal study aiming to collect
data in real-time on health, healthcare, behaviour and psychosocial aspects from people with PCD




We set up an online surveillance system which collects essential epidemiological and clinical data in
real-time directly from people with PCD and publishes continuously summarised results. The study aims
to: 1) describe incidence of COVID-19 in people with PCD, symptoms, course of disease, duration of
illness, treatments and outcomes; 2) identify risk factors for incidence and prognosis; 3) describe the
impact of the pandemic on daily life and healthcare in people with PCD; and 4) assess patients’
experiences, wishes and needs during the COVID-19 pandemic.
Study design
COVID-PCD is an international observational cohort study using anonymous online questionnaires to
collect information directly from people with PCD (clinicaltrials.gov registration number: NCT04602481).
It is a participatory research project where people who have PCD have an active role in all stages of
research. The study was requested by PCD support groups from Switzerland, Germany, the UK, the USA
and Australia and set up in collaboration with a study team at the University of Bern, Switzerland, and the
University of Southampton, UK. The study is designed for three age groups: children below 14 years,
adolescents between 14 and 17 years, and adults aged 18 years or more. For children, the questionnaires
are addressed to the parents, but the child is encouraged to help complete the questionnaires. Adolescents
complete the questionnaires themselves. The study is currently available in English, German and Spanish
with the possibility to expand to more languages.
Inclusion criteria
The study is addressed to people of any age from any country with a confirmed or suspected diagnosis of
PCD. Eligibility of participants is assessed in the baseline questionnaire. We exclude people who answer
“no” to both questions: “Have you been told by a doctor that you have PCD or are likely to have PCD?”
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and “Do you have a reason to believe that you have PCD, even though you have not received a diagnosis
by a doctor?”.
Validating the diagnosis of PCD
Diagnosing PCD is complex and requires several tests to be performed by an experienced team.
Historically, patients may not have been diagnosed according to current standards [25] and in some
patients, even experts are unable to confirm the diagnosis. We validate the diagnosis through questions
asking the patients about results of the diagnostic tests. Many patients have received copies of their test
results and can therefore report the type of tests they have had and their results. For the analysis, we can
stratify the study population into people with a definite diagnosis, people with probable PCD and people
with suspected PCD. During the study, we will further attempt to validate the diagnoses with original
documents. We considered it important to have an inclusive approach and also allow people whose
diagnosis is not proven into the study, because whether or not participants have a formal confirmation of
PCD, they suffer from chronic lung disease and thus should be allowed to contribute their experiences.
Recruitment of study participants
The study is primarily advertised through PCD support groups (table 1) who contact and inform potential
participating people with PCD through social media and e-mail networks and encourage them to take part
in the study. The adverts include a link to the project website (www.covid19pcd.ispm.ch) which leads
directly to the study information and registration. Initially, support groups from the UK (www.pcdsupport.
org.uk), Germany (www.kartagener-syndrom.org/index.php), Switzerland, the USA and Canada (www.
pcdfoundation.org), and Australia (www.pcdaustralia.org.au/) were involved, but more countries are
joining as the study progresses. In regions of the world where PCD-specific patient support groups are
lacking, healthcare specialists seeing people with PCD are asked to help inform patients about the study.
Study procedures
All aspects of the COVID-PCD study are online, including registration and consent and completing the
baseline questionnaire, weekly questionnaires, information on hospitalisation and occasional thematic
questionnaires (figure 1). The website includes detailed information about the study results and allows
participants to register via a link that leads them directly into the study database. At first, participants are
asked to enter their year of birth which directs them to the age-specific study information and
questionnaires. Participants give digital consent to participate and are then asked to enter an e-mail
address where the online questionnaires can be sent to. Immediately after the registration, participants
receive an e-mail with the link to the baseline questionnaire. Adolescents are asked to also enter the e-mail
address of a parent. The parent must give consent before the adolescent receives the baseline
questionnaire. Participants must complete the baseline questionnaire to be enrolled in the study.
One week after completing the baseline questionnaire, and in weekly intervals thereafter, participants
receive short follow-up questionnaires (figure 1). The follow-up questionnaire is not dependent on
participants completing it every week; if participants miss one or more of the follow-up questionnaires,
they will receive the links for the next ones. If a participant is hospitalised due to COVID-19, a link to an
additional short questionnaire is sent. The study also allows thematic questionnaires that focus on specific
topics related to the COVID-19 pandemic to be conceived and sent out. Participants and interested people
can follow the progress of the study on the study website where information on number of recruited
participants, incident COVID-19 infections and selected results from the questionnaires are uploaded
regularly.
TABLE 1 Collaborating primary ciliary dyskinesia (PCD) support organisations
PCD support organisation Country Contact persons Website
Selbsthilfegruppe Primäre Ciliäre Dyskinesie Switzerland Bernhard Rindlisbacher
Verein Kartagener-Syndrom und PCD Germany Hansruedi Silberschmidt www.kartagener-syndrom.org/index.php/verein
PCD Family Support Group UK UK Lucy Dixon www.pcdsupport.org.uk
PCD Foundation USA and Canada Michele Manion www.pcdfoundation.org
PCD Australia Primary Ciliary Dyskinesia Australia Catherine Kruljac www.pcdaustralia.org.au/
Associazione Italiana Discinesia Ciliäre
Primaria Sindrome di Kartagener Onlus
Italy Letizia Andolfi, Sara Bellu www.pcdkartagener.it/associazione/
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Information collected
The baseline questionnaire aims to assess whether the participant has PCD, how the disease was
diagnosed, what the person’s usual symptoms are how severe the disease is, and how it is treated. It also
aims to collect information on the social and environmental context such as people living in the same
household, school and work environment, and physical activity. The baseline questionnaire is divided into
four modules (table 2). Module 1 collects demographic data, contact information and information on
SARS-CoV-2 infections that have occurred prior to study entry. Module 2 collects information on PCD
diagnosis and baseline disease status. Module 3 asks about regular PCD-related symptoms, and module 4
collects information on work, education, lifestyle and health behaviours. Module 3 and 4 are based on the
FOLLOW-PCD questionnaire [26].
The weekly follow-up questionnaire collects information on symptoms and incident SARS-CoV-2
infections, physical activity and time-varying lifestyle factors such as social contacts. If a participant has no
symptoms, the weekly follow-up questionnaire is short. If a participant has symptoms, extra questions
appear asking details about tests for SARS-CoV-2 and other infections, symptoms duration, healthcare
contacts and medication taken.
A short questionnaire is sent in the event of a hospitalisation due to COVID-19. It asks about duration of
the hospitalisation, unit where the patient was treated, treatments and recommendations received after
discharge.
Participant registers

















































FIGURE 1 Timeline and follow-up procedures of the coronavirus disease 2019 (COVID-19) and primary ciliary
dyskinesia (PCD) study.
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Additional thematic questionnaires developed throughout the study focus on special topics related to the
pandemic such as mask use, anxiety, home schooling of children, physical activity or availability of
medications. PCD support organisations and study participants are encouraged to suggest special topics
and participate in developing those questionnaires.
Participant engagement
Participants shape the study in a participatory approach and can influence all aspects of the study
(table 3). They had a decisive role in study design and content of baseline questionnaire. As the study goes
on, participants are encouraged to propose research questions and topics for extra questionnaires, help to
make sure questions are written in a language that is easily understandable, advise on logistics such as how
to approach affected people, and choose results for publication on the website. A patient advisory group
from the European Lung Foundation (ELF) (www.europeanlung.org/en/) includes interested people who
have PCD. The group meets to discuss the COVID-19 outbreak, the PCD-COVID study and questions
relevant to people with PCD.
TABLE 2 Information collected in the coronavirus disease 2019 (COVID-19) and primary ciliary dyskinesia (PCD) study
Questionnaire Timing of distribution Information collected
Registration
questionnaire
At registration Language, year of birth, consent to participate, e-mail address
Baseline
questionnaire
Right after registration Module 1: Demographic information (country, region); contact information in case of
hospital stay; history of COVID-19 infection (tests, test results, severity of
infection, symptoms, people in household who had a COVID-19 infection), other
infections
Module 2: PCD diagnosed by a physician (study eligibility question), PCD in close
family, prior diagnostic tests for PCD and test results (nasal nitric oxide,
high-speed video microscopy, electron microscopy, genetic test), year of PCD
diagnosis, situs inversus, congenital heart defect, bronchiectasis, infections
(bacteria, viruses, fungi), lung function, height, weight, airway clearance therapy,
physiotherapy, oxygen use, antibiotic treatments, hospital stays, flu vaccinations
Comorbidities and their treatments including asthma, hypertension, diabetes,
heart failure, primary immunodeficiency, cancer, inflammatory bowel disease,
and stroke
Module 3 (adapted from the standardised FOLLOW-PCD patient questionnaire [26]):
Current symptoms: Symptoms from nose or ears, hearing problems, headaches,
snoring, coughing, coughing up mucus, wheezing, shortness of breath, chest
pain, fever, general feeling of being unwell
Module 4 (adapted from the standardised FOLLOW-PCD patient questionnaire [26]):
Employment/educational status, profession, days missed from work due to PCD,
mode of transportation to work/school, highest level of education
Level of physical activity, types of sports/activities regularly performed, smoking
status, number of cigarettes per day, years of smoking, year of quitting smoking,
anyone else in household smoking, nutrition (appetite in last 3 months, additional
drink supplements, other supplements), living conditions (type of home, number




Weekly (period can be
adapted)
Current symptoms (in the past 7 days)
Recent COVID-19 infections: Contact with health professional due to COVID-19
infection, medication taken in the past 7 days, change in usual therapies past
7 days
Contact behaviour in the past 7 days: Activities (e.g. stayed at home, went grocery
shopping, went out for exercise, went occasionally or regularly to workplace/
school, etc.), use of public transportation, possible to keep 2 m distance from




If a participant is hospitalised Date of hospitalisation, hospital unit in which patient was treated, duration of
hospital stays, treatments, recommendation after discharge
Thematic
questionnaires
In irregular intervals as
research questions arise
Potential topics: Availability of PCD treatments during COVID-19 pandemic, physical
activity during COVID-19 pandemic, protection measures at schools and
workplaces, e.g. masks, plastic face shields, gloves, etc., anxieties and fears
related to the COVID-19 pandemic
https://doi.org/10.1183/23120541.00843-2020 5
COVID-PCD | E.S.L. PEDERSEN ET AL.
Study database and data protection
The web-based database uses the Research Electronic Data Capture (REDCap) platform developed at
Vanderbilt University (www.project-redcap.org) [27]. The database is hosted by the Swiss medical
registries and data linkage centre (SwissRDL) at the University of Bern, Switzerland, and complies with all
legal requirements for data security and data protection. Access to the database is regulated by a system
with personal passwords. Only study team members who need to perform database management can
access the database. Daily, weekly and monthly back-ups are performed and securely stored at the
SwissRDL servers.
Ethics
The Bern Cantonal Ethics Committee (Kantonale Ethikkomission Bern) has approved this study (Study
ID: 2020-00830). Informed consent to participate in the study is provided at registration into the study.
Study participation is anonymous. Participants can withdraw their consent to participate at any time by
contacting the study team.
Current recruitment status
The study started recruitment on April 30, 2020. By November 2, 2020, 556 people with PCD had
completed the baseline questionnaire (figure 2). Together, participants have already completed a total of
4776 weekly questionnaires over a period of 23 weeks. On average, 50% (range 33–68%) of participants
completed the weekly follow-up questionnaire (figure 2). The study includes people with PCD from 36
countries with the largest numbers from England (n=121; 22%), the USA (n=101; 18%), Germany (n=78;
14%) and Switzerland (n=42, 8%) (table 4). Two-thirds of participants are female (n=340; 61%), and all
age groups are well represented with 172 (31%) <15 years, 136 (24%) aged 15 to 29 years, 154 (28%)
between 30 and 49 years, and 94 (17%) being 50 years or older.
Discussion
The COVID-PCD study is an online surveillance system of COVID-19 in people with PCD which collects
essential information in real-time directly from people with PCD. It is a participatory research project
where people who have PCD have an active role in all stages of research. Summarised results are published
continuously on the website and shared on social media via the PCD support groups to inform
participants, researchers and physicians.
Comparison with other studies
To our knowledge, very few studies investigate the effect of COVID-19 on people with a rare disease and
very few focus on respiratory diseases. A questionnaire survey from the rare diseases clinical research
TABLE 3 Participant involvement in the study
Study step Inputs from PCD support groups
Concept and design of study The idea for the study came from PCD support groups
The study design was developed in close communication between PCD
support groups and the study team
Questionnaire design The content of the baseline and follow-up questionnaires was decided
based on ideas from PCD support group representatives, healthcare
staff and researchers
Wording of the questionnaires was checked by PCD support group
representatives to ensure that the language was understandable and
meaningful for all
Recruitment of participants Study participants are recruited using measures such as:
• PCD support groups social media post links to the study website
• E-mails to PCD support group members
• Presentations about the study at PCD support group meetings and in
newsletters
Choice and interpretation of
results
Summarised results displayed on the website are based on what is most
important for participants
Thematic questionnaires Thematic questionnaires are developed based on suggestions from
participants and PCD support groups
Display of results on study
website
Participants can suggest results to be posted on the website and how to
phrase them
PCD: primary ciliary dykinesia.
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network based in Ohio, USA, collects cross-sectional information on the effect of COVID-19 from people
with all types of rare diseases [28]. A major strength of this study is that recruitment is not happening
through healthcare facilities, but any person with a rare disease and access to the internet can participate
via a link on the study website. This also ensures that people with mild disease or limited access to
healthcare may participate. However, the study is limited to the USA; the questionnaire is short and
collects information only once, and it remains general as it includes people with any kind of rare diseases.
Another research project, the ImmunoCOVID19 study, at the University of Southampton, UK, monitors
COVID-19 in children with primary or secondary immunosuppression (below 18 years) [29]. Recruitment
happens through hospitals. Participants complete a short baseline questionnaire and are followed up
weekly through a short online questionnaire. This study follows participants longitudinally, which makes it
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FIGURE 2 Number of people with primary ciliary dyskinesia (PCD) who enrolled in the study by November 2,
2020 (cumulative) and number and per cent who completed the weekly follow-up questionnaire.
TABLE 4 Country of residence and sex of participants, displayed in total and by age groups
(n=556)
Total 0–14 years 15–29 years 30–49 years 50 years and above
Subjects n 556 172 136 154 94
Country#
England 121 (22) 34 (20) 32 (24) 36 (23) 19 (20)
USA 101 (18) 35 (20) 23 (17) 26 (17) 17 (18)
Germany 78 (14) 34 (20) 9 (7) 21 (14) 14 (15)
Switzerland 42 (8) 8 (5) 16 (12) 5 (3) 13 (14)
Australia 27 (5) 11 (6) 5 (4) 5 (3) 6 (6)
Italy 22 (4) 7 (4) 6 (4) 9 (6) 0
Canada 20 (4) 7 (4) 3 (2) 6 (4) 4 (2)
The Netherlands 18 (3) 2 (1) 8 (6) 5 (3) 3 (3)
Scotland 12 (2) 4 (2) 3 (2) 3 (2) 2 (2)
Denmark 10 (2) 1 (1) 4 (3) 2 (1) 3 (3)
France 10 (2) 3 (2) 2 (1) 2 (1) 3 (3)
Norway 10 (2) 2 (1) 0 6 (4) 2 (2)
Other European countries 60 (11) 14 (8) 19 (14) 22 (14) 5 (5)
Other non-European countries 25 (4) 10 (6) 6 (4) 6 (4) 3 (3)
Sex (n=555)
Male 214 (39) 92 (53) 49 (36) 41 (27) 32 (34)
Female 340 (61) 80 (47) 86 (63) 113 (73) 61 (66)
Other 1 (0) 0 1 (1) 0 0
Data are presented as n (%). #: countries with n⩾10 displayed in table, countries with n<10 were
categorised into other European countries and other non-European countries.
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rare respiratory diseases use data from hospital records. The European Cystic Fibrosis Society set up the
COVID-CF project in Europe where data from national cystic fibrosis (CF) registries are pooled to identify
people with CF who have been infected with SARS-CoV-2 [30, 31]. By October 4, 144 cases of COVID-19
in patients with CF were documented in 18 countries. A study in Spain investigated incidence of
SARS-CoV-2 from March to May 2020 in 2500 CF patients registered in the national registry using
information from hospital records [32]. However, these studies only identify the most severe cases of
SARS-CoV-2 infections that result in hospitalisations. Mild cases are missed, and this type of study biases
the results towards more severe infections.
Strengths and limitations
A key feature and major strength of this study is the participatory approach where people with PCD
together with the team of researchers shape the study, recruit participants, and interpret and decide which
results should be presented on the study website. The close collaboration between people with PCD and
researchers ensures the relevance for participants and makes sure that study material is meaningful for
people with PCD. It may also positively influence response rate in the weekly follow-up questionnaires.
Another strength is the web-based study design, which allows participants to contribute their data to the
database in real-time. This limits the risk of recall bias as participants only report symptoms from the last
7 days, and there is no delay caused by data entry as participants enter data themselves into the database.
The PCD support groups provided essential inputs to the study questionnaires and study design. The
broad inclusion criteria allowing people of any age from anywhere in the world to participate is another
strength of the study. The COVID-PCD study is one of the largest international studies including data
reported directly from people with a rare disease. COVID-PCD not only covers infection rates, severity of
symptoms and prognosis of COVID-19 but also studies factors related to the COVID-19 pandemic such as
social isolation and physical activity habits. Additionally, special topics can be studied at short notice using
extra questionnaires that are sent out once and can be proposed by participants themselves.
One limitation of the study is the convenience sampling method. It is difficult to estimate the response
rate without information on how many people with PCD have seen the study information, and it is
difficult to know if the study participants are representative of the average population of people with PCD.
Conclusion
The COVID-19 pandemic evolves quickly and gathering data fast on how COVID-19 affects people with
rare chronic diseases is essential for informing patients, physicians and policy makers. First results on
recruitment from the COVID-PCD study show a good representation from many regions in the world
across all age groups. COVID-PCD is an essential resource to follow people with PCD throughout the
COVID-19 pandemic, help empower patients and in providing a platform for communication between
patients, physicians and researchers.
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